Donor lymphocyte infusion after allogeneic stem cell transplantation

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic stem cell transplantation (allo-SCT) is a primary treatment for hematological malignancies and non-malignant disorders.
• Disease relapse post-allo-SCT remains a significant clinical challenge.
• Harnessing the donor's immune system presents a promising approach to manage or prevent relapse.

Purpose of the Study:

• To analyze the efficacy of donor lymphocyte infusion (DLI) in treating hematological diseases after allo-SCT.
• To evaluate the therapeutic and pre-emptive applications of DLI.
• To provide insights into optimizing DLI strategies for improved patient outcomes.

Main Methods:

• Review of clinical data and literature on DLI efficacy in various hematological diseases.
• Analysis of treatment outcomes in patients receiving DLI post-allo-SCT.
• Focus on DLI's role in both treating active relapse and preventing disease recurrence.

Main Results:

• DLI demonstrates significant efficacy in managing hematological disease relapse following allo-SCT.
• Both therapeutic (post-relapse) and pre-emptive (prevention) DLI strategies show clinical benefit.
• The effectiveness of DLI varies depending on the specific hematological disease and patient context.

Conclusions:

• DLI is a valuable therapeutic option for addressing relapse after allo-SCT.
• Strategic application of DLI, considering its therapeutic or pre-emptive use, can improve disease control.
• Further research may refine DLI protocols for enhanced efficacy in hematological disorder management.